Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) study group

Pediatric Infectious Disease Journal

Volumn 22, Issue SUPPL. 2, 2003, Pages

  Carbonell Estrany, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Epidemiology; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

CARDIOVASCULAR DISEASE; CHILD; CHILD HOSPITALIZATION; CHRONIC LUNG DISEASE; CONFERENCE PAPER; EUROPE; GESTATIONAL AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPAIN; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LENGTH OF STAY; LUNG DISEASES; MALE; PRACTICE GUIDELINES; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEASONS; SPAIN; TREATMENT OUTCOME;

EID: 0037329314     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200302001-00008     Document Type: Conference Paper

References (14)

1. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 1998:2084-111.
2. Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first years of life. Am J Epidemiol 1991;133:1135-51.
3. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 96(Suppl B):S1-7, 2002.
4. Navas L, Wang E, de Carvalho V, Robinson J, and the Pediatric Investigators Collaborative Network on Infections in Canada. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348-54.
5. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 2003;22:S13-20.
6. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000;19:592-7.
7. Carbonell-Estrany X, Quero J for the IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20:874-9.
8. Langley JM, LeBlanc JC, Wang EE, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a pediatric investigators collaborative network on infections in Canada study. Pediatrics 1997;100:943-6.
9. Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a pediatric investigators collaborative network on infections in Canada (PICNIC) study. J Pediatr 1997;131:113-7.
10. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. Eur J Pediatr 1998;157:215-20.
11. Carbonell Estrany X, Quero Jimenez J. Recommendations for the prevention of respiratory syncytial virus infections. Standards Committee of the Spanish Society of Neonatology. Board of Directors of the Spanish Society of Neonatology (in Spanish). An Esp Pediatr 2000;52:372-4.
12. Carbonell-Estrany X, Quero Jimenez J. Guidelines for respiratory syncytial virus prophylaxis: an update (in Spanish). An Esp Pediatr 2002;56:334-6.
13. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
14. Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcome in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immuneglobulin. Am J Med 2002;112:627-33.